硼替佐米在NHL应用.pptVIP

GOELAMS 法国 Elderly mantle cell lymphoma (MCL) patients (pts) do not benefit from dose-intensive chemotherapy upfront.1 from June 2007 to December 2009, 39 pts were enrolled in the study with a majority of males (n=30). * Conclusion: The results of the current phase II trial indicate that the RiPAD+C regimen, integrating bortezomib, is feasible and well tolerated as a first line therapy in elderly MCL pts. Historical comparisons suggest that this regimen compares favourably to the classical R-CHOP regimen in terms of response rates and duration. * * Rosenwald et al applied a hierarchical-clustering algorithm to group the lymphomas according to the expression of 100 genes that distinguished between germinal-center B-cell–like and activated B-cell–like diffuse large-B-cell lymphomas at a significance level of P0.001 in the previous analysis and found three large subgroups. One had a high level of expression of the genes characteristic of germinal-center B-cell–like diffuse large-B-cell lymphoma and normal germinal-center B cells, another expressed genes characteristic of activated B-cell–like diffuse large-B-cell lymphoma and mitogenically activated blood B cells, and the third, termed type 3 diffuse large-B-cell lymphoma, did not express either set of genes at a high level. The heterogeneity of expression within this third subgroup indicates that it may consist of more than one type of diffuse large-B-cell lymphoma. * * * * * * * * * * 中国大陆有约~25%的NHL是T细胞淋巴瘤，中国香港有18.3%的NHL是T细胞淋巴瘤 * * 肝脾T细胞淋巴瘤（HSTCL）CTCL 皮肤T细胞性淋巴瘤 , 间变性大细胞性淋巴瘤（ALCL），约60%-85%左右ALCL病例表达间变性淋巴瘤激酶（anaplasticlymphomakinase，ALK）融合蛋白，这是由于2号染色体上的ALK基因位点的畸变所致,越来越多研究表明原发性系统性ALCL中ALK阳性和ALK阴性病例其表现有明显差异, ALK阴性原发性系统性ALCL更多见于年龄大的病人，且这些病人的预后较差,众多的研究表明ALK阳性的ALCL其预后明显好于ALK阴性的病例。 血管免疫母细胞性 T 细胞淋巴瘤（AITL） 外周T细胞性淋巴瘤非特异型 PTCL-U 临床预后差 – 5年生存率:PTCL-NOS (32%), angioimmunoblastic (32%), ATLL (14%), extranasal NK/T-cell lymphoma (9%) * Rituximab is approved for the treatment of CD20+ relapsed/refractory follicular lymphoma (